Revolution Medicines has received US Food and Drug Administration approval for a once-daily pill designed to block several forms of the RAS protein, which CNBC reports helps drive tumour growth in many pancreatic cancers.
Key facts
- The FDA has approved a pancreatic cancer drug from Revolution Medicines, according to CNBC.
- The treatment is a once-daily pill.
- It is designed to block several forms of the RAS protein.
- RAS helps drive tumour growth in many pancreatic cancers, CNBC reports.
Revolution Medicines has secured approval from the US Food and Drug Administration for a pancreatic cancer treatment, according to CNBC. The drug is a once-daily pill.
The medicine is designed to block several forms of the RAS protein, according to CNBC. RAS is a protein that helps drive tumour growth in many pancreatic cancers, the outlet reports.
CNBC’s report focuses on the drug’s mechanism and dosing. It does not detail pricing or availability timelines.
Why it matters
The approval adds a once-daily oral treatment option for pancreatic cancer that, according to CNBC, targets the RAS protein involved in tumour growth.
Frequently asked questions
What does the newly approved Revolution Medicines drug do?
According to CNBC, the drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
How is the drug taken?
CNBC reports that the treatment is a once-daily pill.
Why is targeting the RAS protein important?
The RAS protein helps drive tumor growth in many pancreatic cancers, according to CNBC, making it a key target for treatment.